Core Viewpoint - Hong Kong's Chief Executive, John Lee, highlighted the robust development of life and health sciences in Hong Kong, emphasizing the potential for economic and strategic opportunities through the integration of government, industry, academia, research, and investment systems [1] Group 1: Economic Opportunities - The rise of independently developed innovative drugs in China presents significant economic opportunities for Hong Kong [1] - Hong Kong aims to attract more pharmaceutical companies to conduct clinical trials and treatments for rare diseases, advanced cancer drugs, and innovative therapies [1] Group 2: Clinical Trial Enhancements - Efforts will be made to improve patient recruitment and trial initiation efficiency [1] - The establishment of the "Greater Bay Area Clinical Trial Collaboration Platform" will facilitate synchronized trials in Hong Kong and Shenzhen [1] Group 3: Talent Development and Events - Plans are underway to establish an "International Clinical Trial Academy" to cultivate clinical trial talent in the Greater Bay Area [1] - The government will host international summits and forums to further promote the sector [1]